Incyte | INCY - 销售成本



金融业
股票价格
USD
资产
USD 7.34B
现金及等价物
USD 4.02B
销售成本
USD 104.5M
流动资产
USD 5.48B
流动负债
USD 1.49B
债务
USD 39.43M
EBIT
USD 344.17M
EBITDA
USD 367.97M
员工
2.62K
EPS每股收益
USD 1.81
股本和储备
USD 5.62B
销售毛利
USD 1.17B
债务利息支出
USD 569K
利息收入
USD 33.69M
贷款资金
USD 29.41M
市值
USD 21.81B
净收入
USD 303.33M
营业费用
USD 5.62B
营业利润
USD 324.17M
普通股股本
USD 199.95M
PE价格收益
15.35
税前利润
USD 343.6M
销售收入
USD 1.27B
销售和管理费用
USD 328.1M
股票
USD 115.62M
贸易债权人
USD 228.62M
应收帐款人
USD 1.05B


销售成本 更改 日
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agenus USD 642K 399K 2025-09
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amgen USD 1.6B 187M 2026-03
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Exelixis USD 26.48M 7.91M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
MacroGenics USD 10.12M 34.18M 2025-12
Merck USD 2.94B 380M 2026-03
Moderna USD 955M 503M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.46B 83M 2026-03
Novartis USD 3.54B 7M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03